Recruiting PHASE1 INTERVENTIONAL 2-arm NCT06568614

An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-89894 (SYH2039) Tablets in Patients With Advanced Solid Tumors

Sponsor: BeOne Medicines

Conditions Advanced or Metastatic MTAP-deleted Solid Tumors

Interventions BG-89894

Updated 5 times since 2024 Last updated: Feb 3, 2026 Started: Oct 12, 2024 Primary completion: Jun 30, 2026 Completion: Dec 30, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced or Metastatic MTAP-deleted Solid Tumors and is currently actively recruiting participants. BeOne Medicines leads this study, which shows 5 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE1
Nov 2025 — Feb 2026 [monthly]

Recruiting PHASE1
Jul 2025 — Nov 2025 [monthly]

Recruiting PHASE1
Mar 2025 — Jul 2025 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Mar 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BeOne Medicines

Data source: BeOne Medicines

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Baltimore, United States , Beijing, China , Blacktown, Australia , Chengdu, China , Fairfax, United States , Fitzroy, Australia , Guangzhou, China , Nanjing, China , Nanning, China and 8 more locations